Drug intelligence / Profile preview

MIC2231

Development stage: Preclinical
Lead developer: Micar Innovation
Modality: Small Molecules

Overview

MIC2231 is a small molecule drug candidate currently in preclinical development by Micar Innovation for the treatment of Stiff Person Syndrome (SPS). SPS is a rare, progressive neurological disorder characterized by muscle stiffness and painful spasms, often linked to autoimmune dysfunction. MIC2231 is part of Micar Innovation's proprietary pipeline of wholly-owned therapeutics. While the company has confirmed its development for this rare disease indication, the specific biological target and mechanism of action for MIC2231 remain undisclosed.

Beyond the preview

Go deeper on MIC2231.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIC2231.

Explore the full profile